Skip to main content
Toggle navigation
Login
Search
Home
Browse by Poster Title
Home
Browse by Poster Title
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
#
Sort by
Title
P
LB-023
PATH TO REGULATORY REVIEW OF A QUANTITATIVE SYSTEM PHARMACOLOGY (QSP) MODEL
Favorite
PII-191
PEDIATRIC CLINICAL TRIAL DESIGNS FOR TESTOSTERONE REPLACEMENT THERAPY.
Favorite
PII-082
PERSPECTIVES ABOUT THE DEVELOPMENT AND IMPLEMENTATION OF PHARMACOGENOMIC CLINICAL DECISION SUPPORT TOOLS IN RURAL AND UNDERSERVED COMMUNITIES
Favorite
PII-205
PERSPECTIVES ON PHARMACOGENETIC-GUIDED TOBACCO CESSATION IN AN AMERICAN INDIAN POPULATION
Favorite
CT-003
PERSPECTIVES ON PHARMACOGENETIC-GUIDED TOBACCO CESSATION IN AN AMERICAN INDIAN POPULATION
Favorite
PII-083
PHARMACOGENOMIC ANALYSIS OF THE PHARMACOKINETIC ENDPOINTS FROM A DRUG-DRUG INTERACTION STUDY OF ENCORAFENIB IN COMBINATION WITH BINIMETINIB USING THE INJE COCKTAIL IN CANCER PATIENTS.
Favorite
PII-084
PHARMACOGENOMICS OF DILATED CARDIOMYOPATHY: A GENETIC DETERMINANT OF MYOCARDIAL RECOVERY
Favorite
PII-029
PHARMACOKINETIC EVALUATION OF GB1211 IN A NOVEL TABLET FORMULATION, ADMINISTERED UNDER FASTED AND FED CONDITIONS, AND COMPARED TO GB1211 CAPSULES, IN HEALTHY VOLUNTEERS
Favorite
AI-008
PHARMACOKINETIC MODEL-GUIDED ENOXAPARIN DOSING IN THE NICU: RETROSPECTIVE ANALYSIS TO PLAN FOR PROSPECTIVE FEASIBILITY TRIAL.
Favorite
LB-024
PHARMACOKINETIC MODEL-GUIDED ENOXAPARIN DOSING IN THE NICU: RETROSPECTIVE ANALYSIS TO PLAN FOR PROSPECTIVE FEASIBILITY TRIAL.
Favorite
PII-131
PHARMACOKINETIC PARAMETER ESTIMATION OF GENTAMICIN IN AN OBESE HEMODIALYSIS PATIENT: A CASE REPORT
Favorite
LB-025
PHARMACOKINETICALLY-GUIDED DOSING OF ORAL SORAFENIB IN PATIENTS WITH PEDIATRIC HEPATOCELLULAR CARCINOMA
Favorite
PII-060
PHARMACOKINETICS (PK) AND SOLUBLE MET (SMET) PHARMACODYNAMICS (PD) OF REGN5093, A MET X MET BISPECIFIC ANTIBODY, IN PATIENTS (PTS) WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC)
Favorite
PII-061
PHARMACOKINETICS (PK) OF MIRZOTAMAB CLEZUTOCLAX (MIRZO-C) IN PATIENTS WITH RELAPSED AND REFRACTORY SOLID TUMORS: FIRST IN HUMAN STUDY RESULTS
Favorite
PII-132
PHARMACOKINETICS AND SAFETY OF MAVACAMTEN IN HEALTHY CHINESE SUBJECTS WITH DIFFERENT CYP2C19 PHENOTYPES
Favorite
CT-012
PHARMACOKINETICS OF BT8009, A BICYCLE TOXIN CONJUGATE (BTC), IN PATIENTS WITH SOLID TUMOR MALIGNANCIES AND VARIOUS DEGREES OF RENAL FUNCTIONS
Favorite
PII-062
PHARMACOKINETICS OF BT8009, A BICYCLE TOXIN CONJUGATE (BTC), IN PATIENTS WITH SOLID TUMOR MALIGNANCIES AND VARIOUS DEGREES OF RENAL FUNCTIONS
Favorite
PII-133
PHARMACOKINETICS OF EDARAVONE - COMPARISON OF EXPOSURE BETWEEN JAPANESE AND NON-JAPANESE BY POPULATION PHARMACOKINETIC ANALYSIS.
Favorite
PII-134
PHARMACOKINETICS OF INFIGRATINIB AND ITS ACTIVE METABOLITES IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC CANCER OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA HARBORING FGFR2 GENE AMPLIFICATION
Favorite
PII-135
PHARMACOKINETICS OF MONOCLONAL ANTIBODIES THROUGHOUT PREGNANCY: A SYSTEMATIC LITERATURE REVIEW
Favorite
PII-063
PHARMACOKINETICS OF TARLATAMAB, A DELTA LIKE LIGAND-3 (DLL3) TARGETED HALF-LIFE EXTENDED BISPECIFIC T-CELL ENGAGER (BITE) IMMUNOTHERAPY IN ADULT PATIENTS WITH PREVIOUSLY TREATED SMALL CELL LUNG CANCER (SCLC)
Favorite
PII-136
PHARMACOKINETICS OF TRASTUZUMAB DERUXTECAN (T-DXD) IN SUBJECTS WITH HER2-LOW METASTATIC BREAST CANCER
Favorite
PII-137
PHARMACOKINETICS, SAFETY AND TOLERABILITY OF ABBV-552 IN HEALTHY ADULT JAPANESE AND HAN CHINESE SUBJECTS
Favorite
PII-139
PHARMACOMETRICS-BASED APPROACH TO FIRST-IN-HUMAN INTRAVENOUS DOSE DETERMINATION FOR SRP-6004 IN PATIENTS WITH LIMB GIRDLE MUSCULAR DYSTROPHY 2B
Favorite
PII-140
PHARMCOKINETIC AND PHARMACODYNAMIC RELATIONSHIPS OF INTRANASALLY ADMINISTERED AND INTRAMUSCULARLY INJECTED EPINEPHRINE
Favorite
PII-030
PHASE 1 EVALUATION OF THE SAFETY, TOLERABILITY AND PLASMA AND CEREBROSPINAL FLUID PHARMACOKINETICS OF THE ADENOSINE A1R/A3R AGONIST AST-004 AFTER INTRAVENOUS INFUSION IN HEALTHY VOLUNTEERS
Favorite
PT-014
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL OF DRUG DELIVERY IN THE FEMALE REPRODUCTIVE TRACT
Favorite
PII-174
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL TO ASSESS THE IMPACT OF GENETIC VARIABILITY IN PATIENTS RECEIVING DEXMEDETOMIDINE.
Favorite
PT-011
PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING WITH PAIRED PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF LEVETIRACETAM IN PATIENTS WITH EXTERNAL VENTRICULAR DRAINS.
Favorite
PII-175
PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR PANTOPRAZOLE IN CHILDREN WITH OBESITY.
Favorite
PII-176
PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING FOR ASSESSMENT OF THE DRUG-DRUG INTERACTION POTENTIAL OF ZAVEGEPANT
Favorite
PII-206
PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING FOR PREGNANCY.
Favorite
LB-026
PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING FOR THE PREDICTION OF BCRP-MEDIATED DRUG INTERACTIONS USING R STATISTICAL SOFTWARE
Favorite
PII-177
PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO EVALUATE THE GASTRIC ACID MODIFIER EFFECT ON RIMEGEPANT EXPOSURE
Favorite
LB-027
PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO PREDICT HUMAN DOSE OF MITHRAMYCIN ANALOGUE FOR THE TREATMENT OF EWING SARCOMA
Favorite
LB-028
PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO SUPPORT PEDIATRIC DOSING OF OLVEREMBATINIB IN CHILDREN WITH RELAPSED OR REFRACTORY PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Favorite
PII-141
PILOT FEASIBILITY STUDY OF AN ORAL CYP3A4/2C19 PROBE COCKTAIL TO PREDICT BORTEZOMIB CLEARANCE IN MULTIPLE MYELOMA PATIENTS
Favorite
CT-004
PIPERACILIN PHARMACOKINETICS AND TARGET ATTAINMENT IN PEDIATRIC LIVER TRANSPLANT RECIPIENTS.
Favorite
PII-207
PIPERACILIN PHARMACOKINETICS AND TARGET ATTAINMENT IN PEDIATRIC LIVER TRANSPLANT RECIPIENTS.
Favorite
PII-038
PK/PD OF RIFAMPICIN, ISONIAZID, PYRAZINAMIDE, AND ETHAMBUTOL IN MACROPHAGES INFECTED WITH M. TUBERCULOSIS.
Favorite
PII-039
PLERIXAFOR AS PATHOGEN AGNOSTIC PROPHYLAXIS OR ADVUVANT TREATMENT
Favorite
PII-142
POPULATION EXPOSURE–RESPONSE ANALYSIS SUPPORTS EFFICACY OUTCOMES OF GARADACIMAB IN PATIENTS WITH HEREDITARY ANGIOEDEMA.
Favorite
PII-143
POPULATION PHARMACOKINETIC (PK) MODEL OF AB521, A SMALL MOLECULE INHIBITOR OF HIF-2α, IN HEALTHY PARTICIPANTS.
Favorite
PII-144
POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF NGM707, AN ILT2/ILT4 DUAL ANTAGONIST ANTIBODY IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS.
Favorite
PII-064
POPULATION PHARMACOKINETIC MODEL FOR THE TGFβR1 INHIBITOR PF-06952229 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS
Favorite
PII-145
POPULATION PHARMACOKINETIC MODELING OF ALNUCTAMAB, A BCMA-BINDING T CELL ENGAGER, TO CHARACTERIZE THE BIOAVAILABILITY AND PHARMACOKINETICS IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)
Favorite
PII-146
POPULATION PHARMACOKINETIC MODELING OF CAMRELIZUMAB IN PATIENTS WITH VARIOUS CANCER TYPES, INCLUDING ADVANCED HEPATOCELLULAR CARCINOMA.
Favorite
PII-147
POPULATION PHARMACOKINETIC MODELING OF NGM438 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS.
Favorite
PII-148
POPULATION PHARMACOKINETIC MODELING OF RIVOCERANIB IN HEALTHY SUBJECTS AND PATIENTS WITH VARIOUS CANCER TYPES, INCLUDING ADVANCED HEPATOCELLULAR CARCINOMA (HCC).
Favorite
LB-029
POPULATION PHARMACOKINETICS (PK) AND PHARMACODYNAMIC (PD) ANALYSES OF MULTIPLE INTRAVENOUS INFUSIONS OF NX210C PEPTIDE IN HEALTHY ELDERLY VOLUNTEERS (HEVS)
Favorite
PII-182
POPULATION PHARMACOKINETICS (PK) AND PK/PHARMACODYNAMICS ANALYSES TO REFINE PHASE 3 DOSE OF SETRUSUMAB IN PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA: RESULTS FROM PHASE 2 OF THE ORBIT STUDY
Favorite
PII-065
POPULATION PHARMACOKINETICS (POPPK) OF ABBV-383, A B-CELL MATURATION ANTIGEN (BCMA) × CD3 BISPECIFIC T-CELL-REDIRECTING ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).
Favorite
PII-066
POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSES OF ZOLBETUXIMAB IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Favorite
PII-183
POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-07265803 AND ITS METABOLITE IN PATIENTS WITH LAMIN A/C RELATED DILATED CARDIOMYOPATHY.
Favorite
PII-149
POPULATION PHARMACOKINETICS AND TUMOR GROWTH INHIBITION MODELING OF AN ANTI-CLAUDIN 18.2 ADC TO SUPPORT DRUG DEVELOPMENT DECISION-MAKING
Favorite
LB-030
POPULATION PHARMACOKINETICS MODEL OF PYRAZINAMIDE TO OPTIMIZE TUBERCULOSIS TREATMENT: AN INTERETHNIC COHORT STUDY OF DIABETES MELLITUS EFFECT ON DRUG EXPOSURE.
Favorite
LB-031
POPULATION PHARMACOKINETICS OF BORTEZOMIB: MODEL-BASED META-ANALYSIS
Favorite
PII-150
POPULATION PHARMACOKINETICS OF ENROFLOXACIN AND FLORFENICOL IN THE GIANT DANIO (DEVARIO AEQUIPINNATUS) FOLLOWING ORAL AND BATH ADMINISTRATION
Favorite
TIP-005
POPULATION PHARMACOKINETICS OF LEVOFLOXACIN IN KOREAN AND INDONESIAN TUBERCULOSIS PATIENTS: THE INFLUENCE OF RENAL FUNCTION AND DIABETES MELLITUS ON CLEARANCE.
Favorite
PII-067
POPULATION PHARMACOKINETICS OF ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA.
Favorite
PII-151
POPULATION PHARMACOKINETICS OF REZVILUTAMIDE (SHR3680) WITH TIME-VARYING AND SATURABLE RELATIVE BIOAVAILABLITY IN PROSTATE CANCER PATIENTS
Favorite
PT-002
POST-TRANSCRIPTIONAL GENE REGULATION AND ANTIDEPRESSANT TREATMENT RESPONSE: FUNCTIONAL CHARACTERIZATION OF ELAVL2 RNA-BINDING PROTEIN IN IPSC-DERIVED NEURONS.
Favorite
PII-085
POTENTIAL HEALTHCARE DISPARITIES AMONG PATIENTS WHO REGISTER FOR NOVEL PHARMACOGENETICS CONSULTATION SERVICE
Favorite
PII-152
PREDICT: A MACHINE LEARNING ALGORITHM FOR PREDICTING PHARMACOKINETIC PROFILES
Favorite
AI-005
PREDICTING REMISSION IN ACUTE BIPOLAR DEPRESSION: A MACHINE LEARNING STUDY WITH CROSS-TRIAL REPLICATION
Favorite
PT-009
PREDICTING REMISSION IN ACUTE BIPOLAR DEPRESSION: A MACHINE LEARNING STUDY WITH CROSS-TRIAL REPLICATION
Favorite
LB-032
PREDICTING THE POTENTIAL FOR CANNABIDIOL INDUCED DRUG-DRUG INTERACTIONS WITH MAJOR CYP450 ENZYMES USING MODEL-BASED APPROACHES
Favorite
PWII-005
PREDICTION OF OVERALL SURVIVAL IN MELANOMA PATIENTS: A TUMOR GROWTH INHIBITION OVERALL SURVIVAL MODELING FRAMEWORK
Favorite
PT-008
PREDICTION OF OVERALL SURVIVAL IN MELANOMA PATIENTS: A TUMOR GROWTH INHIBITION OVERALL SURVIVAL MODELING FRAMEWORK
Favorite
PII-153
PREDICTION OF PFS BASED ON TUMOR GROWTH INHIBITION METRICS IN HER2 POSITIVE BREAST CANCER PATIENTS FOLLOWING HER2 ADC FS-1502 TREATMENT
Favorite
PII-154
PREDICTIVE MODELING OF TACROLIMUS DOSE REQUIREMENTS AND TRANSPLANTATION OUTCOME IN LUNG TRANSPLANT RECIPIENTS ON SYSTEMIC AZOLE ANTIFUNGALS
Favorite
PII-224
PREDICTORS OF ALZHEIMER'S DISEASE AND RELATED DEMENTIA (ADRD) IN A HYPERTENSION (HTN) POPULATION WITHIN THE STATE OF FLORIDA USING ELECTRONIC HEALTH RECORD (EHR)-BASED DATA.
Favorite
PII-023
PREVALENCE, AGE AND SEX DISTRIBUTION OF PATIENTS WITH CHRONIC HEALTH CONDITIONS IN A LARGE HEALTHCARE SYSTEM
Favorite
CT-005
PREVALENCE, AGE AND SEX DISTRIBUTION OF PATIENTS WITH CHRONIC HEALTH CONDITIONS IN A LARGE HEALTHCARE SYSTEM
Favorite
PII-178
PROSPECTIVE APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING TO INFORM THE DESIGN OF A CLINICAL DRUG-DRUG INTERACTION (DDI) STUDY: CASE STUDY OF MEZIGDOMIDE
Favorite
